Free tool
FAERS Monitor: Filspari
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216403 or its brand name (Filspari, Sparsentan). Reports on generic versions are filed under their own applications.
Reports
6,767
Serious
1,116
16% of reports
Hospitalization
477
Death reported
37
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness984
- fatigue887
- hypotension750
- off label use456
- nausea455
- headache403
- product use in unapproved indication390
- product administration error369
- peripheral swelling354
- pruritus317
- product dose omission issue278
- blood pressure decreased268
- glomerular filtration rate decreased253
- drug ineffective231
- blood creatinine increased221
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 632 |
| 2024 | 1,221 |
| 2025 | 2,395 |
| 2026 | 2,508 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,392 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| glomerular filtration rate decreasedSignal | 253 | 65.3 | 57.8 | 15,642 |
| product administration errorSignal | 369 | 57.8 | 52.3 | 20,179 |
| blood pressure decreasedSignal | 268 | 12.6 | 11.2 | 2,843 |
| hypotensionSignal | 750 | 11.7 | 10.9 | 7,342 |
| blood creatinine increasedSignal | 221 | 10.6 | 9.3 | 1,901 |
| peripheral swellingSignal | 354 | 7.2 | 6.5 | 1,878 |
| dizzinessSignal | 984 | 6.1 | 5.8 | 4,325 |
| product use in unapproved indicationSignal | 390 | 4.9 | 4.4 | 1,218 |
| fatigueSignal | 887 | 3.5 | 3.3 | 1,678 |
| product dose omission issueSignal | 278 | 2.9 | 2.6 | 359 |
| pruritusSignal | 317 | 2.6 | 2.3 | 307 |
| headache | 403 | 2.0 | 1.8 | 206 |
| nausea | 455 | 1.8 | 1.6 | 163 |
| off label use | 456 | 1.6 | 1.5 | 112 |
| drug ineffective | 231 | 0.5 | 0.5 | 93 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.